An interventional study of lumetry and Arterialized Capillary Blood Gas Analysis in Pulmonary Disease, Chronic Obstructive and Hypercapnia, sponsored by Lumetry Diagnostics GmbH. Not yet recruiting at 1 site in Austria. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Lumetry Diagnostics GmbH · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria — 14 open to participants now, 20 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Austria.
Among the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria, this one is the 43rd largest by planned enrollment of the 83 interventional ones that give a count, is one of 2 that started in 2026, is one of 19 with no phase, reaches primary completion later than 14 of the 19 other live ones, and was the 96th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Austria, United States, Argentina and 15 more countries
Ages 40–75
Sanofi · Sites in Austria, United States, Argentina and 19 more countries
Ages 40–85
Medical University of Graz · Sites in Austria, Switzerland, United Kingdom
Ages 18+
Apreo Health, Inc. · Sites in Austria, United States, Germany and 2 more countries
Ages 40–84
GlaxoSmithKline · Sites in Austria, United States, Argentina and 13 more countries
Ages 40–80
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 40 · Phase 4 14
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 304 across the 83 interventional studies, 877 across the 12 observational. Of the 66 that completed or were terminated, 44 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 96 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Lumetry Diagnostics GmbH as lead sponsor.
Lumetry Diagnostics GmbH has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Austria that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07102823Medical University of GrazClinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-30 |
| NCT05008081Wim JanssensThe CATALINA Study | 2027-03 |
| NCT06035120Pulmonx CorporationAn Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | 2027-06-30 |
| NCT06891755Apreo Health, Inc.Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 96 studies in Pulmonary Disease, Chronic Obstructive with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to evaluate how well the lumetry device performs in two areas: estimating the level of carbon dioxide in the arterial blood (paCO2) and screening for chronic obstructive pulmonary disease (COPD).
lumetry is a small handheld device that analyzes exhaled breath. Participants breathe normally into the device for 60 seconds. No forced or maximal breathing maneuvers are required for the lumetry measurement.
Today, the carbon dioxide level in the blood is usually measured with a blood gas analysis, which requires a blood sample. COPD is usually diagnosed with spirometry, a lung function test that requires maximal breathing effort and trained staff.
In this study, adults with COPD of different severity and adults without known lung disease each attend a single study visit. All participants perform one lumetry breath measurement and a standard lung function test (forced spirometry). Participants with COPD also give a small capillary blood sample from the earlobe for blood gas analysis, and some of them additionally have their carbon dioxide level measured through the skin (transcutaneous measurement). By comparing the lumetry results with these established methods, the study assesses how accurately the device estimates the carbon dioxide level in the blood. By comparing the lumetry COPD screening result with spirometry and the confirmed clinical diagnosis, the study assesses how reliably the device distinguishes between people with and without COPD.
The study is conducted at one hospital in Vienna, Austria, and will include 300 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with chronic obstructive pulmonary disease (COPD), stratified by severity (50 GOLD I/II, 50 GOLD III, 50 GOLD IV), and 150 adults without known lung function pathologies. All participants perform a single 60-second lumetry measurement of normal resting breathing, followed by forced spirometry. Participants with COPD additionally undergo arterialized capillary blood gas analysis, with a subgroup of 50 participants with COPD (GOLD III and IV) additionally undergoing transcutaneous carbon dioxide monitoring.
Device: lumetry · Diagnostic Test: Arterialized Capillary Blood Gas Analysis · Diagnostic Test: Transcutaneous Carbon Dioxide Monitoring · Diagnostic Test: Forced Spirometry
Handheld capnography and spirometry device that estimates the arterial partial pressure of carbon dioxide (paCO2) and provides a COPD screening result from a single 60-second measurement of normal resting breathing. The device also provides the end-tidal carbon dioxide value (petCO2), which serves as comparator for the paCO2 estimate.
Capillary blood sample from the arterialized earlobe, collected immediately after the lumetry measurement. Reference standard for paCO2. Performed in participants with COPD only.
Non-invasive measurement of carbon dioxide through the skin (tcPCO2), recorded as close in time as possible to the lumetry measurement and blood sampling. Comparator for paCO2 estimation. Performed in a subgroup of 50 participants with COPD.
Standard lung function test performed at the end of the study visit in all participants. Together with the documented clinical diagnosis, reference standard for the COPD screening result.
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and End-Tidal Carbon Dioxide (petCO2)
In participants with chronic obstructive pulmonary disease (COPD), the carbon dioxide level in the arterial blood (paCO2) estimated by lumetry is compared with the value measured in a capillary blood sample (blood gas analysis, reference standard). The average size of the difference, regardless of direction (mean absolute deviation), is calculated for lumetry and for the standard breath-based value (end-tidal carbon dioxide, petCO2). The outcome is the MAD of petCO2 minus the MAD of lumetry, so a positive value means lumetry is closer to the blood gas value.
Time frame: Day 1 (single study visit)
Sensitivity of the lumetry COPD Screening Result
Percentage of participants with COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as positive by the lumetry COPD screening result.
Time frame: Day 1 (single study visit)
Specificity of the lumetry COPD Screening Result
Percentage of participants without COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as negative by the lumetry COPD screening result.
Time frame: Day 1 (single study visit)
Standard Deviation of the Differences Between lumetry-Estimated paCO2 and Blood Gas paCO2
In participants with chronic obstructive pulmonary disease (COPD), the difference between the lumetry-estimated arterial carbon dioxide level (paCO2) and the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for each participant. The outcome is the standard deviation of these differences, describing the precision of the lumetry estimate. Unit: millimeters of mercury (mmHg).
Time frame: Day 1 (single study visit)
Percentage of lumetry paCO2 Estimates Within 8 mmHg of Blood Gas paCO2
In participants with COPD, the percentage of lumetry paCO2 estimates that differ by 8.0 millimeters of mercury (mmHg) or less in either direction from the paCO2 measured by capillary blood gas analysis (reference standard).
Time frame: Day 1 (single study visit)
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and Transcutaneous Carbon Dioxide (tcPCO2)
In a subgroup of 50 participants with COPD, the average size of the difference, regardless of direction (mean absolute deviation), from the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for lumetry and for transcutaneous carbon dioxide monitoring (tcPCO2). The outcome is the difference between these two averages. Unit: millimeters of mercury (mmHg).
Time frame: Day 1 (single study visit)
Number of Participants With Adverse Events, Adverse Device Effects, or Device Deficiencies
Number of participants with at least one adverse event, adverse device effect, or device deficiency related to the study procedures, recorded during the study visit.
Time frame: Day 1 (single study visit)
Cross-Validated Sensitivity of a Re-Trained lumetry COPD Screening Algorithm
Exploratory analysis. Sensitivity of a re-trained version of the lumetry machine learning algorithm for identifying participants with chronic obstructive pulmonary disease (COPD), estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis.
Time frame: Day 1 (single study visit)
Cross-Validated Specificity of a Re-Trained lumetry COPD Screening Algorithm
Exploratory analysis. Specificity of a re-trained version of the lumetry machine learning algorithm for identifying participants without COPD, estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis.
Time frame: Day 1 (single study visit)
Cross-Validated Mean Absolute Deviation of Re-Trained lumetry paCO2 Estimates From Blood Gas paCO2
Exploratory analysis. Average size of the difference, regardless of direction (mean absolute deviation), between the arterial carbon dioxide level (paCO2) estimated by a re-trained version of the lumetry machine learning algorithm and the paCO2 measured by capillary blood gas analysis, estimated by stratified repeated k-fold cross-validation in participants with COPD. Unit: millimeters of mercury (mmHg).
Time frame: Day 1 (single study visit)
Plan to share: No
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 88 industry-sponsored interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 35. This study's planned 12 months is below that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →